Search

Search Constraints

You searched for: Issue Volume 32(2022)Supplement 2

Search Results

111. 2022-RA-1130-ESGO Effect of imiqiumod treatment on HLA-G expression in high-grade cervical lesions. (20th October 2022)

114. 2022-RA-1134-ESGO First real-life data on niraparib maintenance in newly-diagnosed advanced ovarian cancer: a descriptive analysis of the Temporary Authorisation for Use (ATU) cohort. (20th October 2022)

115. 2022-RA-1136-ESGO A single-cell map of rare ovarian cancer. (20th October 2022)

116. 2022-RA-1137-ESGO Use of an allogeneic, cell-based vaccine DCP-001 in high grade Serous Ovarian cancerpatients after primary treatment; A phase I clinical trial. (20th October 2022)

119. 2022-RA-1143-ESGO Does Robotic surgery improve surgical outcomes and survival compared to conventional laparoscopy in gynecological cancer?. (20th October 2022)

120. 2022-RA-1144-ESGO Management of immune-related adverse events in patients with solid tumours treated with dostarlimab in the GARNET study. (20th October 2022)